PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to$50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results Preliminary Q1 2025Q1 2024Revenue$36.9 million$38.8 millionInstrument revenue$10.8 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and oth ...